Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Common Equity (2016 - 2026)

Veracyte's Common Equity history spans 14 years, with the latest figure at $1.3 billion for Q4 2025.

  • On a quarterly basis, Common Equity rose 11.36% to $1.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 billion, a 11.36% increase, with the full-year FY2025 number at $1.3 billion, up 11.36% from a year prior.
  • Common Equity hit $1.3 billion in Q4 2025 for Veracyte, up from $1.3 billion in the prior quarter.
  • Over the last five years, Common Equity for VCYT hit a ceiling of $1.3 billion in Q4 2025 and a floor of $971.2 million in Q2 2021.
  • Historically, Common Equity has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2021.
  • Biggest five-year swings in Common Equity: skyrocketed 329.45% in 2021 and later fell 5.32% in 2022.
  • Tracing VCYT's Common Equity over 5 years: stood at $1.1 billion in 2021, then decreased by 1.94% to $1.1 billion in 2022, then decreased by 2.89% to $1.0 billion in 2023, then increased by 12.63% to $1.2 billion in 2024, then increased by 11.36% to $1.3 billion in 2025.
  • Business Quant data shows Common Equity for VCYT at $1.3 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.2 billion in Q2 2025.